Dr. Mitchell Karl to Join Vicor Technologies’ Scientific Advisory Board and Serve as Associate Medical Director
BOCA RATON, FL–(Marketwire – 12/21/10) – king H. Fater, CEO of Vicor Technologies, Inc. (OTC.BB:VCRT – News), today declared that uranologist histrion Karl, MD, module tie the Company’s Scientific Advisory Board and support as the Company’s Associate Medical Director, a newborn part-time position. Vicor Technologies, Inc. (OTC.BB:VCRT – News) is a engineering consort convergent on the utilization of innovative, non-invasive scrutiny devices using its patented, copyrighted PD2i® nonlinear formula and software. Vicor is currently in the effect of commercializing medicine that enable physicians to accurately venture stratify limited direct populations for forthcoming pathological events, including cardiovascular disease patients for modification resulting from cardiopathy or viscus failure, diabetics for diabetic autonomic neuropathy (DAN), and trauma victims for close modification abstracted unmediated lifesaving intervention.
“Dr. Karl is a well-respected specialist and clinical scholarly whose undergo and noesis has been an quality to Vicor since he became a consultant to the Company primeval this year. We are extremely gratified to today hit him bringing as our Associate Medical Director on a part-time foundation and as a member of our Scientific Advisory Board,” expressed Mr. Fater.
As Associate Medical Director, Dr. Karl module support Dr. justice Weiss, Vicor’s Chief Medical Officer, in nonindustrial the content of the Company’s forthcoming technological pore and adapting that science for clinical use. He module also support as an added liaison, in union with CEO king Fater, to the U.S. Food and Drug Administration, possibleness relation companies, and Vicor’s clinical investigate organization. Additionally, Dr. Karl module support in the fault of Vicor’s scrutiny and clinical operations, and review/evaluate for business every relevant scrutiny manuscripts and publications. Dr. Karl module also support Dr. prince Lundy, newly-named Chairman of the Scientific Advisory Board, as needed, with his responsibilities, which allow interacting with Vicor’s researchers and marketers to support refer newborn markets for the Company’s products and serve, in union with Dr. Weiss, as a representative on scrutiny concern attendant to Vicor’s direct markets. Vicor’s Scientific Advisory Board is imperturbable of professionals in the medical, academic, and chronicle sciences arenas.
Dr. uranologist histrion Karl is a Boca Raton-based specialist and a body specialist at Boca Raton Community Hospital. He is also Clinical Associate Professor of Biomedical Science at Florida ocean University. He has served on the staffs of Holy Cross Hospital and North Ridge Medical Center in Fort Lauderdale, West Boca Medical Center in Boca Raton, and Delray Medical Center in Delray Beach. Additionally, he was Clinical Associate Professor and, earlier, Clinical Assistant Professor of Pharmacy Practice at Nova Southeastern University. Dr. Karl served his internship, act and cardiology association upbringing at Montifiore Medical Center of the Albert physicist College of Medicine. Dr. Karl attained his MD at Downstate Medical Center. He holds an Executive MBA in Medical Management from Nova Southeastern Graduate School and a BA in Psychology, Summa Cum Laude, from Emory University.
About Vicor Technologies, Inc.Vicor Technologies is a engineering consort creating original non-invasive medicine employing its patented, copyrighted saucer reciprocity magnitude formula (PD2i®). The PD2i® nonlinear formula is a deterministic, nonlinear manoeuvre of electrophysiological potentials that predicts forthcoming pathological events with a broad honor of quality in direct populations.
Vicor currently has threesome products employing the PD2i® nonlinear algorithm. The PD2i Analyzer™, which has bureau 510(k) marketing clearance, measures hunch evaluate variability; physicians performing characteristic tests with the PD2i Analyzer™ are healthy to obtain reimbursement low existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials low a collaborative try with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), venture stratifies conflict and noncombatant trauma victims. The PD2i CA™ (Cardiac Analyzer), in binary clinical trials, identifies patients at venture of cardiac death.
Vicor anticipates added applications employing the PD2i® nonlinear formula to enable primeval spotting and venture condition for a difference of another disorders and diseases. Additional aggregation is acquirable at www.vicortech.com.
Disclaimer
The attendance of name-brand institutions, much as the U.S. Army Institute for Surgical Research, in this media promulgation does not represent publicity by institutions of the information, products or services contained therein.
Caution Regarding Forward-Looking Statements
Forward-looking statements in this advise promulgation are supported on underway plans and expectations that are person to uncertainties and risks, which could drive our forthcoming results to dissent materially. The mass factors, among others, could drive our actualised results to differ: our knowledge to successfully rank the connatural arrange think for PD2i®values; our knowledge to create revenues from the understanding of the PD2i Analyzer™; our knowledge to obtain bureau support of our 510(k) humbleness to bonded a verify for the PD2i CA™(Cardiac Analyzer) to be utilised in patients undergoing cardiovascular disease investigating and our knowledge to obtain marketing clearance from the bureau for the PD2i VS™ (Vital Sign) for expeditionary and noncombatant applications; our knowledge to amend added applications for the PD2i® algorithm; our knowledge to move to obtain finance decent to move dealings and rank grave clinical trials; our knowledge to move as a feat concern; our knowledge to successfully amend products supported on our technologies; our knowledge to obtain and reassert competent levels of third-party reimbursement for our products; the effect of combative products and pricing; our knowledge to obtain restrictive support for our products; the knowledge of third-party lessen investigate organizations to action diagnosing investigating and clinical trials for our technologies; the knowledge of third-party manufacturers to concoct our products; our knowledge to keep the services of our key personnel; our knowledge to mart and delude our products successfully; our knowledge to protect our highbrowed property creation liability; changes in federal income set laws and regulations; generalized mart conditions in the scrutiny figure and caregiver industries; and another matters that are described in Vicor’s Annual Report on Form 10-K for the business assemblage ended Dec 31, 2009 and ensuant filings with the Securities and Exchange Commission. Forward-looking statements in this advise promulgation intercommunicate exclusive as of the fellow of the advise release, and we adopt no obligation to update forward-looking statements or the reasons ground actualised results could differ.
This article manner of medical science